FDA Orange Book
Generic for Parnate
Parnate contains tranylcypromine. Orange Book status for every listed strength, the approved generic makers, and the listed patents and exclusivities.
Source: FDA Orange Book data file dated 2026-10-09. Publisher page
Yes. The generic name for Parnate is tranylcypromine. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
Run it in Rivvi
Map Parnate and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
Parnate products in the Orange Book
| Form and route | Strength | Brand status | Brand TE | Active generics | Generic TE codes |
|---|---|---|---|---|---|
| tablet, oral | EQ 10MG BASE | Marketed (Rx) | AB | 3 | AB |
NDA 012342, held by ADVANZ PHARMA (US) CORP. Active generics are ANDA products in the Orange Book prescription list with the same ingredient, dosage form, route and strength.
Approved generic tranylcypromine
| Company | ANDA | TE code | Approved | Strengths |
|---|---|---|---|---|
| STRIDES PHARMA INTERNATIONAL AG | 040640 | AB (A-rated, therapeutically equivalent) | June 29, 2006 | EQ 10MG BASE |
| NOVITIUM PHARMA LLC | 206856 | AB (A-rated, therapeutically equivalent) | April 17, 2018 | EQ 10MG BASE |
| CROSSMEDIKA SA | 213503 | AB (A-rated, therapeutically equivalent) | June 27, 2022 | EQ 10MG BASE |
Parnate NDC codes
Questions
Is there a generic for Parnate?
Yes. The generic name for Parnate is tranylcypromine. 3 companies hold an active FDA approval (ANDA) for a generic version in the Orange Book. Therapeutic equivalence codes: AB.
What is the generic name for Parnate?
The active ingredient in Parnate is tranylcypromine, per the FDA Orange Book.
What does a therapeutic equivalence code mean?
In the Orange Book, codes that start with A (such as AB) mean FDA considers the product therapeutically equivalent to the reference drug. Codes that start with B mean FDA does not, at this time, consider the product therapeutically equivalent.